Rome, Nov 17. (Adnkronos Health) – “Myasthenia gravis is undergoing a phase of profound transformation. Thanks to research advancements, a rare autoimmune disease, characterized by muscle weakness and often unpredictable symptoms, can now be addressed with increasingly personalized therapeutic strategies.” However, if “therapeutic innovation in myasthenia gravis represents a scientific response to controlling a rare disease that until recently lacked dedicated treatments, it also poses a challenge for the entire healthcare system: the evaluation of new treatments cannot be limited to measuring clinical efficacy or acquisition cost, but must consider outcomes relevant to the individual, the social impact of the disease, the appropriateness of use, and the repercussions on the organization of regional services. In a constantly evolving international context, it is fundamental for Italy to adopt a strategic and long-term vision, capable of supporting therapeutic innovation through adequate resource planning and sustainable and predictable funding models. Recognizing the value of innovation means considering not only immediate costs, but also the clinical, social, and organizational benefits it can generate, creating the conditions for research progress to translate into concrete, appropriate, and equitable treatment opportunities for those who can benefit from them.” This is the central message of the Policy Paper ‘The value of innovation in myasthenia gravis’, presented in Rome at Palazzo Baldassini during a meeting promoted by Omar – Observatory for Rare Diseases, with the non-conditioning contribution of Ucb Pharma. The document stems from a discussion between expert clinicians and representatives of patient associations gathered in the Myasthenia Gravis Alliance and identifies 4 guiding principles and 5 healthcare policy priorities to bring to the attention of national and regional institutions.
“For those living with myasthenia gravis, pharmacological innovation allows for greater possibilities of disease control, regaining autonomy, and being able to plan their lives without being constantly conditioned by the unpredictability of symptoms. New therapies are already changing the prospects for many people, but we must ensure that these advancements are truly accessible to all who can benefit from them. This is the purpose of the Myasthenia Gravis Alliance’s work: to transform people’s needs into concrete priorities for institutions,” states Mariangela Pino, Italian Association for Myasthenia and Immunodegenerative Diseases Amici del Besta Odv, Lazio. Innovation has already changed treatment prospects, but its value cannot be measured solely by the cost of drugs, experts emphasize. Myasthenia gravis, in fact, can profoundly compromise personal autonomy, work continuity, and the ability to plan one’s life. According to data from the international My real world MG study, 40% of those involved had to take time off work, and 11.5% left their jobs due to the disease. Furthermore, 36% require caregiver support, with significant consequences also on family and professional organization.
The Policy Paper therefore identifies 5 priority areas of intervention: protecting conditions that favor research and the availability of pharmaceutical innovation; ensuring appropriate and timely access pathways; strengthening the multidimensional evaluation of therapeutic benefits, also considering quality of life and social impact; consolidating care networks and connections between specialist centers and the territory; promoting participatory governance that integrates research, clinical experience, and the voice of patients. The availability of increasingly targeted treatments requires not only specialized skills and adequate diagnostic tools, but also care pathways capable of accompanying people throughout the entire treatment journey. Otherwise, territorial differences in service organization and accessibility risk translating into different therapeutic opportunities for patients with similar needs. “Today we have therapeutic opportunities that we did not have until a few years ago and that allow us to pursue more ambitious treatment goals. But pharmacological innovation alone is not enough. It is necessary to rethink the organization of care, enhancing the expertise of specialized centers and building structured connections with territorial services. Not all activities necessarily have to be concentrated in the same hospital: what matters is ensuring shared standards, continuity of care, and the possibility of accessing treatments even near people’s places of residence. Therapeutic innovation must also become an opportunity to innovate care models,” highlights Francesco Habetswallner, director of Uoc Neurofisiopatologia Aorn Cardarelli in Naples.